Abstract 123P
Background
A novel fusion gene of EML4-ALK and ROS 1 has been identified in a subset of non-small-cell lung cancers (NSCLCs). Patients with the ALK-EML4 and ROS1 fusion gene demonstrate unique clinicopathological characteristics and treatment with targeted therapy led to improved survivals.
Methods
Data of advanced NSCLC patients diagnosed between 2016 and 2022 with ALK and ROS1 positivity were analyzed. Detection of ALK was done by IHC or fluorescent in situ hybridization (FISH) and ROS1 was done by FISH.
Results
A total of 776 advanced NSCLC patients between 2016 and 2022 were tested for ALK of which 63(8.1%) were positive. The median age at presentation was 50 years (range,19-80 years). Of 63 patients, 34(54%) were males and 29(46%) were females. Cough (83%) was the most common symptom at presentation followed by dyspnea (73%), anorexia (59%) weight loss (59%) and chest pain (43%). The median duration of symptoms was 3 months. 44(86%) patients were never smokers and 9(14%) patients had history of smoking or tobacco usage. The most common site of metastases was opposite lung(59%), bone(50%) followed by pleural effusion(41%). Brain metastasis were seen in 13(21%) patients. Detection of ALK positivity was done by IHC and FISH in 45(72%) and 18(28%) patients respectively. Of 63 patients, 52 patients received atleast 4 months of treatment and were assessed for survival. First-line therapy was crizotinib, chemotherapy followed by maintenance crizotinib, ceritinib, alectinib in 40(77%), 4(7.7%), 6(11.5%) and 2(3.8%) patients. The median PFS was 16 months (range, 4-52). At a median follow up of 14 months, the 1-year progression free and overall survival was 71% and 75%. The 2 year and 3 year OS were 54% and 30% . Out of 322 patients tested for ROS1, 9(2.8%) were positive for ROS1 translocation and received first-line therapy with Crizotinib. The one year PFS and OS were 75% and 89%.
Conclusions
ALK and ROS1 positivity was seen in 8.1% and 2.8% of advanced NSCLC patients. Majority of patients were never smokers. Opposite lung and bone were the most common site of metastases. 3/4th of the patients had one-year survival rate and the survival rates in the real world are better than reported in the randomized studies. Crizotinib is well tolerated in majority of patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Nizam's Institute of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract